Abstract
The precise mechanisms leading to platelet-targeted autoimmunity in immune thrombocytopenia (ITP) are not known. Cellular checkpoints normally regulate immunological self-reactivity during the development of B and T cells through cell deletion, receptor editing, induction of anergy, and extrinsic cellular suppression. When these checkpoints fail, tolerance to self-antigens may be lost. In this review, we summarize the various immune mechanisms contributing to the development of ITP and relate them back to the checkpoint model of autoimmunity. These mechanisms, including increased levels of lymphocyte growth factors, resistance to death signals, and loss of T-regulatory function, result in an environment permissive to the development of platelet-reactive B and T cells. The mechanisms that lead to thrombocytopenia once tolerance for platelet antigens is lost are examined, including complement-dependent and apoptotic pathways. An improved understanding of ITP pathogenesis will ultimately guide the development of better therapies.
KEYWORDS
Immune thrombocytopenia - self-tolerance - platelets - megakaryocytes - autoantibody
REFERENCES
-
1
Warner M N, Moore J C, Warkentin T E, Santos A V, Kelton J G.
A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura.
Br J Haematol.
1999;
104
(3)
442-447
-
2
McMillan R.
Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes.
J Pediatr Hematol Oncol.
2003;
25
(Suppl 1)
S57-S61
-
3
Cines D B, Bussel J B, Liebman H A, Luning Prak E T.
The ITP syndrome: pathogenic and clinical diversity.
Blood.
2009;
113
(26)
6511-6521
-
4
Goodnow C C, Sprent J, Fazekas de St Groth B, Vinuesa C G.
Cellular and genetic mechanisms of self tolerance and autoimmunity.
Nature.
2005;
435
(7042)
590-597
-
5
Hartley S B, Cooke M P, Fulcher D A et al..
Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death.
Cell.
1993;
72
(3)
325-335
-
6
Hsu B L, Harless S M, Lindsley R C, Hilbert D M, Cancro M P.
Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators.
J Immunol.
2002;
168
(12)
5993-5996
-
7
Thien M, Phan T G, Gardam S et al..
Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches.
Immunity.
2004;
20
(6)
785-798
-
8
Cheema G S, Roschke V, Hilbert D M, Stohl W.
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Arthritis Rheum.
2001;
44
(6)
1313-1319
-
9
Zhang J, Roschke V, Baker K P et al..
Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus.
J Immunol.
2001;
166
(1)
6-10
-
10
Groom J, Kalled S L, Cutler A H et al..
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.
J Clin Invest.
2002;
109
(1)
59-68
-
11
Emmerich F, Bal G, Barakat A et al..
High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura.
Br J Haematol.
2007;
136
(2)
309-314
-
12
Zhu X J, Shi Y, Sun J Z et al..
High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia.
J Clin Immunol.
2009;
29
(5)
603-610
-
13
Zhu X J, Shi Y, Peng J et al..
The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia.
Blood.
2009;
114
(26)
5362-5367
-
14
Zhou Z, Chen Z, Li H et al..
BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura.
Autoimmunity.
2009;
42
(2)
112-119
-
15
Gu D, Ge J, Du W et al..
Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications.
Autoimmunity.
2009;
42
(8)
692-698
-
16
Palmer E.
Negative selection—clearing out the bad apples from the T-cell repertoire.
Nat Rev Immunol.
2003;
3
(5)
383-391
-
17
Sakaguchi N, Takahashi T, Hata H et al..
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.
Nature.
2003;
426
(6965)
454-460
-
18
Gong Q, Cheng A M, Akk A M et al..
Disruption of T cell signaling networks and development by Grb2 haploid insufficiency.
Nat Immunol.
2001;
2
(1)
29-36
-
19
McCarty N, Paust S, Ikizawa K, Dan I, Li X, Cantor H.
Signaling by the kinase MINK is essential in the negative selection of autoreactive thymocytes.
Nat Immunol.
2005;
6
(1)
65-72
-
20
Olsson B, Andersson P O, Jacobsson S, Carlsson L, Wadenvik H.
Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura.
Thromb Haemost.
2005;
93
(1)
139-144
-
21
Olsson B, Andersson P O, Jernås M et al..
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura.
Nat Med.
2003;
9
(9)
1123-1124
-
22
Salgame P, Abrams J S, Clayberger C et al..
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.
Science.
1991;
254
(5029)
279-282
-
23
Romagnani S.
Th1 and Th2 in human diseases.
Clin Immunol Immunopathol.
1996;
80
(3 Pt 1)
225-235
-
24
Mosmann T R, Coffman R L.
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.
Annu Rev Immunol.
1989;
7
145-173
-
25
Mosmann T R, Sad S.
The expanding universe of T-cell subsets: Th1, Th2 and more.
Immunol Today.
1996;
17
(3)
138-146
-
26
Liblau R S, Singer S M, McDevitt H O.
Th1 and Th2 CD4 + T cells in the pathogenesis of organ-specific autoimmune diseases.
Immunol Today.
1995;
16
(1)
34-38
-
27
Druet P, Sheela R, Pelletier L.
Th1 and Th2 cells in autoimmunity.
Clin Exp Immunol.
1995;
101
(Suppl 1)
9-12
-
28
Semple J W, Milev Y, Cosgrave D et al..
Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity.
Blood.
1996;
87
(10)
4245-4254
-
29
Panitsas F P, Theodoropoulou M, Kouraklis A et al..
Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response.
Blood.
2004;
103
(7)
2645-2647
-
30
Ogawara H, Handa H, Morita K et al..
High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura.
Eur J Haematol.
2003;
71
(4)
283-288
-
31
Gu D, Chen Z, Zhao H et al..
Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia.
Hum Immunol.
2010;
71
(6)
586-591
-
32
Zhang J, Ma D, Zhu X, Qu X, Ji C, Hou M.
Elevated profile of Th17, Th1 and Tc1 cells in patients with immune thrombocytopenic purpura.
Haematologica.
2009;
94
(9)
1326-1329
-
33
Zhu X, Ma D, Zhang J et al..
Elevated interleukin-21 correlated to Th17 and Th1 cells in patients with immune thrombocytopenia.
J Clin Immunol.
2010;
30
(2)
253-259
-
34
Huetz F, Carlsson L, Tornberg U C, Holmberg D.
V-region directed selection in differentiating B lymphocytes.
EMBO J.
1993;
12
(5)
1819-1826
-
35
Yancopoulos G D, Alt F W.
Regulation of the assembly and expression of variable-region genes.
Annu Rev Immunol.
1986;
4
339-368
-
36
Tonegawa S.
Somatic generation of antibody diversity.
Nature.
1983;
302
(5909)
575-581
-
37
Fischer P, Jendreyko N, Hoffmann M et al..
Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia.
Br J Haematol.
1999;
105
(3)
626-640
-
38
Roark J H, Bussel J B, Cines D B, Siegel D L.
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation.
Blood.
2002;
100
(4)
1388-1398
-
39
van Dijk-Härd I, Feld S, Holmberg D, Lundkvist I.
Increased utilization of the VH6 gene family in patients with autoimmune idiopathic thrombocytopenic purpura.
J Autoimmun.
1999;
12
(1)
57-63
-
40
Söderström I, van Dijk-Härd I, Feld S, Hillörn V, Holmberg D, Lundkvist I.
Altered VH6-D-JH repertoire in human insulin-dependent diabetes mellitus and autoimmune idiopathic thrombocytopenic purpura.
Eur J Immunol.
1999;
29
(9)
2853-2862
-
41
Kato T, Kurokawa M, Sasakawa H et al..
Analysis of accumulated T cell clonotypes in patients with systemic lupus erythematosus.
Arthritis Rheum.
2000;
43
(12)
2712-2721
-
42
Matsumoto Y, Yoon W K, Jee Y et al..
Complementarity-determining region 3 spectratyping analysis of the TCR repertoire in multiple sclerosis.
J Immunol.
2003;
170
(9)
4846-4853
-
43
Sun W, Nie H, Li N et al..
Skewed T-cell receptor BV14 and BV16 expression and shared CDR3 sequence and common sequence motifs in synovial T cells of rheumatoid arthritis.
Genes Immun.
2005;
6
(3)
248-261
-
44
Hedlund-Treutiger I, Elinder G, Wigzell H, Grunewald J, Wahlström J.
T cell receptor V gene usage by CD4+ and CD8+ peripheral blood T lymphocytes in immune thrombocytopenic purpura.
Acta Paediatr.
2004;
93
(5)
633-637
-
45
Shimomura T, Fujimura K, Takafuta T et al..
Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura.
Br J Haematol.
1996;
95
(4)
732-737
-
46
Zhang X L, Li Y Q, Chen S H et al..
The feature of clonal expansion of TCR Vbeta repertoire, thymic recent output function and TCRzeta chain expression in patients with immune thrombocytopenic purpura.
Int J Lab Hematol.
2009;
31
(6)
639-648
-
47
Stasi R, Del Poeta G, Stipa E et al..
Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura.
Blood.
2007;
110
(8)
2924-2930
-
48
Rui L, Vinuesa C G, Blasioli J, Goodnow C C.
Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling.
Nat Immunol.
2003;
4
(6)
594-600
-
49
Carreno B M, Bennett F, Chau T A et al..
CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
J Immunol.
2000;
165
(3)
1352-1356
-
50
Peng J, Liu C, Liu D et al..
Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura.
Blood.
2003;
101
(7)
2721-2726
-
51
Zhang X L, Peng J, Sun J Z et al..
Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura.
J Thromb Haemost.
2008;
6
(1)
158-165
-
52
von Boehmer H.
Mechanisms of suppression by suppressor T cells.
Nat Immunol.
2005;
6
(4)
338-344
-
53
Mellanby R J, Thomas D C, Lamb J.
Role of regulatory T-cells in autoimmunity.
Clin Sci (Lond).
2009;
116
(8)
639-649
-
54
Sakakura M, Wada H, Tawara I et al..
Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura.
Thromb Res.
2007;
120
(2)
187-193
-
55
Yu J, Heck S, Patel V et al..
Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura.
Blood.
2008;
112
(4)
1325-1328
-
56
Ling Y, Cao X, Yu Z, Ruan C.
Circulating dendritic cells subsets and CD4 + Foxp3 + regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.
Eur J Haematol.
2007;
79
(4)
310-316
-
57
Stasi R, Cooper N, Del Poeta G et al..
Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.
Blood.
2008;
112
(4)
1147-1150
-
58
Li Z, Mou W, Lu G et al..
Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.
Int J Hematol.
2011;
93
(1)
91-98
-
59
Bao W, Bussel J B, Heck S et al..
Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.
Blood.
2010;
116
(22)
4639-4645
-
60
Semple J W, Freedman J.
Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia.
Blood.
1991;
78
(10)
2619-2625
-
61
Kuwana M, Kaburaki J, Kitasato H et al..
Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura.
Blood.
2001;
98
(1)
130-139
-
62
Sukati H, Watson H G, Urbaniak S J, Barker R N.
Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura.
Blood.
2007;
109
(10)
4528-4538
-
63
Aster R H.
Molecular mimicry and immune thrombocytopenia.
Blood.
2009;
113
(17)
3887-3888
-
64
Stasi R, Sarpatwari A, Segal J B et al..
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review.
Blood.
2009;
113
(6)
1231-1240
-
65
Arnold D M, Bernotas A, Nazi I et al..
Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review.
Haematologica.
2009;
94
(6)
850-856
-
66
Takahashi T, Yujiri T, Shinohara K et al..
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura.
Br J Haematol.
2004;
124
(1)
91-96
-
67
Maeda S, Ogura K, Yoshida H et al..
Major virulence factors, VacA and CagA, are commonly positive in Helicobacter pylori isolates in Japan.
Gut.
1998;
42
(3)
338-343
-
68
Nardi M A, Liu L X, Karpatkin S.
GPIIIa-(49-66) is a major pathophysiologically relevant antigenic determinant for anti-platelet GPIIIa of HIV-1-related immunologic thrombocytopenia.
Proc Natl Acad Sci U S A.
1997;
94
(14)
7589-7594
-
69
Li Z, Nardi M A, Karpatkin S.
Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia.
Blood.
2005;
106
(2)
572-576
-
70
Karpatkin S, Nardi M.
Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia.
J Clin Invest.
1992;
89
(2)
356-364
-
71
Nardi M, Tomlinson S, Greco M A, Karpatkin S.
Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia.
Cell.
2001;
106
(5)
551-561
-
72
Sakaguchi M, Sato T, Groopman J E.
Human immunodeficiency virus infection of megakaryocytic cells.
Blood.
1991;
77
(3)
481-485
-
73
Sundell I B, Koka P S.
Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression.
Curr HIV Res.
2006;
4
(1)
107-116
-
74
Zhang W, Nardi M A, Borkowsky W, Li Z, Karpatkin S.
Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.
Blood.
2009;
113
(17)
4086-4093
-
75
Ballem P J, Segal G M, Stratton J R, Gernsheimer T, Adamson J W, Slichter S J.
Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance.
J Clin Invest.
1987;
80
(1)
33-40
-
76
Kuter D J, Rummel M, Boccia R et al..
Romiplostim or standard of care in patients with immune thrombocytopenia.
N Engl J Med.
2010;
363
(20)
1889-1899
-
77
Cheng G, Saleh M N, Marcher C et al..
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Lancet.
2011;
377
(9763)
393-402
-
78
Dighiero G, Lymberi P, Guilbert B, Ternynck T, Avrameas S.
Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins.
Ann N Y Acad Sci.
1986;
475
135-145
-
79
Filion M C, Proulx C, Bradley A J et al..
Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells.
Blood.
1996;
88
(6)
2144-2150
-
80
Shlomchik M J, Marshak-Rothstein A, Wolfowicz C B, Rothstein T L, Weigert M G.
The role of clonal selection and somatic mutation in autoimmunity.
Nature.
1987;
328
(6133)
805-811
-
81
Tsubakio T, Tani P, Woods Jr V L, McMillan R.
Autoantibodies against platelet GPIIb/IIIa in chronic ITP react with different epitopes.
Br J Haematol.
1987;
67
(3)
345-348
-
82
Harrington W J, Minnich V, Hollingsworth J W, Moore C V.
Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura.
J Lab Clin Med.
1951;
38
(1)
1-10
-
83
Luk S C, Musclow E, Simon G T.
Platelet phagocytosis in the spleen of patients with idiopathic thrombocytopenic purpura (ITP).
Histopathology.
1980;
4
(2)
127-136
-
84
Panzer S, Szamait S, Bödeker R H, Haas O A, Haubenstock A, Mueller-Eckhardt C.
Platelet-associated immunoglobulins IgG, IgM, IgA and complement C3 in immune and nonimmune thrombocytopenic disorders.
Am J Hematol.
1986;
23
(2)
89-99
-
85
Piguet P F, Vesin C.
Modulation of platelet caspases and life-span by anti-platelet antibodies in mice.
Eur J Haematol.
2002;
68
(5)
253-261
-
86
Leytin V, Mykhaylov S, Starkey A F et al..
Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia.
Br J Haematol.
2006;
133
(1)
78-82
-
87
Usuki Y, Kohsaki M, Nagai K, Ohe Y, Hara H.
Complement-dependent cytotoxic factor to megakaryocyte progenitors in sera from patients with idiopathic thrombocytopenic purpura.
Int J Cell Cloning.
1986;
4
(6)
447-463
-
88
Takahashi R, Sekine N, Nakatake T.
Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation.
Blood.
1999;
93
(6)
1951-1958
-
89
Alimardani G, Guichard J, Fichelson S, Cramer E M.
Pathogenic effects of anti-glycoprotein Ib antibodies on megakaryocytes and platelets.
Thromb Haemost.
2002;
88
(6)
1039-1046
-
90
Karpatkin S.
Autoimmune thrombocytopenic purpura.
Blood.
1980;
56
(3)
329-343
-
91
Kelton J G, Gibbons S.
Autoimmune platelet destruction: idiopathic thrombocytopenic purpura.
Semin Thromb Hemost.
1982;
8
(2)
83-104
-
92
Isaka Y, Kambayashi J, Kimura K et al..
Platelet production, clearance and distribution in patients with idiopathic thrombocytopenic purpura.
Thromb Res.
1990;
60
(2)
121-131
-
93
Cooper N.
Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
Hematol Oncol Clin North Am.
2009;
23
(6)
1317-1327
-
94
Kelton J G, Singer J, Rodger C, Gauldie J, Horsewood P, Dent P.
The concentration of IgG in the serum is a major determinant of Fc-dependent reticuloendothelial function.
Blood.
1985;
66
(3)
490-495
-
95
Kojouri K, Vesely S K, Terrell D R, George J N.
Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.
Blood.
2004;
104
(9)
2623-2634
-
96
Sarpatwari A, Provan D, Erqou S, Sobnack R, David Tai F W, Newland A C.
Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry.
Br J Haematol.
2010;
151
(5)
477-487
-
97
Peerschke E I, Andemariam B, Yin W, Bussel J B.
Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.
Br J Haematol.
2010;
148
(4)
638-645
-
98
Jin Z, El-Deiry W S.
Overview of cell death signaling pathways.
Cancer Biol Ther.
2005;
4
(2)
139-163
-
99
Falcieri E, Bassini A, Pierpaoli S et al..
Ultrastructural characterization of maturation, platelet release, and senescence of human cultured megakaryocytes.
Anat Rec.
2000;
258
(1)
90-99
-
100
Kaluzhny Y, Yu G, Sun S et al..
BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation.
Blood.
2002;
100
(5)
1670-1678
-
101
Bouillet P, Metcalf D, Huang D C et al..
Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.
Science.
1999;
286
(5445)
1735-1738
-
102
De Botton S, Sabri S, Daugas E et al..
Platelet formation is the consequence of caspase activation within megakaryocytes.
Blood.
2002;
100
(4)
1310-1317
-
103
Morison I M, Cramer Bordé E M, Cheesman E J et al..
A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia.
Nat Genet.
2008;
40
(4)
387-389
-
104
Chang M, Nakagawa P A, Williams S A et al..
Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro.
Blood.
2003;
102
(3)
887-895
-
105
McMillan R, Wang L, Tomer A, Nichol J, Pistillo J.
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP.
Blood.
2004;
103
(4)
1364-1369
-
106
Houwerzijl E J, Blom N R, van der Want J J et al..
Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura.
Blood.
2004;
103
(2)
500-506
-
107
Kaushansky K.
Thrombopoietin.
N Engl J Med.
1998;
339
(11)
746-754
-
108
Borge O J, Ramsfjell V, Veiby O P, Murphy Jr M J, Lok S, Jacobsen S E.
Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro.
Blood.
1996;
88
(8)
2859-2870
-
109
Houwerzijl E J, Blom N R, van der Want J J, Vellenga E, de Wolf J T.
Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic thrombocytopenic purpura is in part due to different forms of cell death.
Leukemia.
2006;
20
(11)
1937-1942
-
110
Yang L, Wang L, Zhao C H et al..
Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia.
Blood.
2010;
116
(20)
4307-4316
-
111
Zhang F, Chu X, Wang L et al..
Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura.
Eur J Haematol.
2006;
76
(5)
427-431
-
112
Chow L, Aslam R, Speck E R et al..
A murine model of severe immune thrombocytopenia is induced by antibody- and CD8 + T cell-mediated responses that are differentially sensitive to therapy.
Blood.
2010;
115
(6)
1247-1253
-
113
Li S, Wang L, Zhao C, Li L, Peng J, Hou M.
CD8+ T cells suppress autologous megakaryocyte apoptosis in idiopathic thrombocytopenic purpura.
Br J Haematol.
2007;
139
(4)
605-611
Donald M ArnoldM.D.C.M. M.Sc.
Department of Medicine, McMaster University, 1280 Main Street West
HSC 3V50, Hamilton, ON L8S 4K1 Canada
Email: arnold@mcmaster.ca
